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Abstract 
 
EQUINE SERUM ANTIBODY RESPONSES TO STREPTOCOCCUS EQUI AND 
STREPTOCOCCUS ZOOEPIDEMICUS 
 
 Streptococcus zooepidemicus (Sz) and Streptococcus equi (Se) share 98% DNA 
sequence homology, but display different pathogenic properties. Infection by one 
organism does not cross-protect against the other. To better understand pathogenic 
differences between these organisms and gain information about which proteins are 
expressed in horses with  respiratory or intrauterine Sz infection or with Se infection we 
compared antibody specificities of convalescent sera using ELISA. These comparisons 
were based on sets of 8 and 14 immunoreactive recombinant proteins of Se strain CF32 
and Sz strain NC78, respectively. Sera from donkeys that were previously naturally 
affected with strangles and later developed Sz pneumonia secondary to an experimental 
influenza challenge were also included.  
 Serum antibody responses were quantitatively and qualitatively much greater 
following recovery from strangles than following respiratory Sz infection. Increased 
reactions to Se proteins IdeE2, Se75.3, Se46.8, Se18.9 and Se42.0 were observed for the 
majority of strangles sera but not for sera from respiratory Sz infection cases. Reactions 
of sera from Sz respiratory disease to Sz proteins varied greatly and were mostly to HylC 
and ScpC. Interestingly, sera of donkey recovered from Sz bronchopneumonia did not 
show increased antibody reaction to any of the proteins although these donkeys had 
recovered from clinical strangles 6 months previously. Only 1/5 mares with Sz placentitis 
showed increased serum antibody responses to MAP. In conclusion, adaptive immune 
responses to Se of horses with strangles are stronger and involve a greater number of 
proteins than adaptive immune responses to Sz infection of the lower respiratory tract.  
 In an effort to develop an improved vaccine against Se,  the modified live strain of 
EHV-1, RacH was constructed to express three recombinant antigens of Se SeM, IdeE 
and Se18.9. Two groups of 10 and 2 ponies were vaccinated intramuscularly or 
intranasally, respectively. Another group (n=6) vaccinated with empty RacH served as 
controls. Sera from 2/3 ponies from each vaccination groups and 1/2 serum from IN 
vaccinated ponies showed increased serum neutralizing antibodies to EHV-1. ELISA 
detected no significant increase in antibodies to proteins. Only one IM and IN vaccinated 
pony showed serum bactericidal activity post vaccination.  
Keywords: Streptococcus equi subsp. equi, Streptococcus equi subsp. zooepidemicus, 
serum antibody response, immunogen, vaccine vector, RacH.  
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 1 
Chapter one - Introduction 
S. zooepidemicus and its host restricted clonal derivative S. equi (Jorm et al., 
1994; Webb et al., 2008) share over 98 % DNA sequence homology (Holden et al., 2009) 
and express many of the same or similar proteins (Timoney et al., 2010). Although 
closely related these organisms exhibit important differences in pathogenesis, host-
pathogen interaction, and ability to activate immune responses effective in clearance. 
Furthermore, despite their high genetic homology and similar protein profiles, infection 
by S. zooepidemicus does not confer protection against S. equi and vice versa. 
S. zooepidemicus is the most frequently isolated opportunistic pathogen of horses 
(Timoney et al., 2004) and unlike S. equi permanently colonizes the equine tonsil and 
other body surfaces. On the other hand, S. equi is highly contagious causing purulent 
tonsillitis and pharyngitis with metastasis to one or more lymph nodes of the head and 
neck. Failure of drainage /clearance of the guttural pouch may result in a chronic carrier 
state. In donkeys, S. equi infection is described as a more caseous form of lymphadenitis 
and respiratory S. zooepidemicus infection with more severe bronchopneumonia than in 
horses.   
Unlike S. zooepidemicus, S. equi does not typically persist in the tonsils and has a 
very limited survival time outside its equine host. Horses that maintain the organism 
within the guttural pouch and/or cranial sinuses are responsible for persistence of 
infection as well as introduction of the organism to other herds (Newton et al, 1997 and 
2000; Verheyen et al., 2000). 
Differences in virulence, niche adaptation, tissue attachment and invasion shared 
between the two organisms are suggested to be a result of expression of different proteins 
 
 2 
in S. equi versus S. zooepidemicus. We hypothesized that differences in specificities of 
convalescent serum antibodies would identify proteins of S. equi and S. zooepidemicus 
uniquely expressed in horses with clinical disease caused by each of the organisms. This 
information could potentially be helpful in the development of new diagnostic tools, and 
reveal particularities in antibody specificities of the organ systems involved during 
infection.  
Using ELISA, we compared antibody profiles of convalescent sera collected from 
horses with strangles, respiratory S. zooepidemicus infection and S. zooepidemicus 
placentitis using sets of 8 and 14 surface exposed or secreted recombinant proteins of 
SeCF32 (SeM-N2, SePSe, Se110.0, Se75.3, Se46.8, IdeE2, Se42.0, Se18.9) and SzNC78 
(Enolase, SzM, OppA, MAP, FSR, INLA, Sz115, SzMAC, ScpC, SzP, SKC, AhpC, 
GAPDH, HylC.) respectively. In addition, convalescent sera from donkeys that were 
previously naturally affected with strangles and latter developed S. zooepidemicus 
pneumonia secondary to an experimental influenza challenge were also studied.  
S. equi is highly contagious and enters the host via mucosal epithelium; therefore 
protection from infection is likely to be facilitated by a strong mucosal immune response 
to block invasion of tonsillar tissue. Given the importance of mucosal antibodies for 
protection against strangles, an improved vaccine that elicits mucosal antibodies is highly 
desirable. Several studies with intranasal vaccines designed to stimulate mucosal 
immunity using a variety of mucosal adjuvants and carriers failed to demonstrate 
protection against experimental challenge. In an effort to develop a novel improved 
vaccine against S. equi, a modified live strain of EHV-1 RacH was constructed as a 
vector for 3 antiphagocytic proteins of S. equi, SeM, IdeE and Se18.9. 
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RacH is a replication incompetent viral vector remarkable for its ability to 
efficiently deliver foreign genes to a variety of cells of different origin. It stably and 
effectively expresses immunogenic proteins even at low concentrations, has a high 
capacity for packing foreign DNA (more than 100kb) and capability to induce humoral 
and cell mediated immunity in horses and several other animal species (Osterrieder et al., 
1999; Trapp et al., 2005).  
The rationale for selection of proteins was based on the distinctive hallmark of S. 
equi infection, its ability to resist phagocytosis. Proteins involved in this resistance 
include SeM, which requires hyaluronic acid capsule for proper function, Se18.9 and 
IdeE. In addition, the N-termini of SeM and Se18.9 are uniquely expressed by S. equi 
which further support its important role in virulence.  
 SeM is highly immunogenic and antibodies raised against it have robust opsonic 
properties (Timoney et al., 1997). SeM binds fibrinogen and thereby reduces deposition 
of C3b on the bacterial surface.  In addition, it shares very limited homology (23%) with 
its S. zooepidemicus homologue, SzM. Although, immunization with recombinant SeM in 
mice and horses has stimulated high antibody levels, protection against challenge was 
established only in mice but not horses (Timoney et al., 2007; Sheoran et al., 2002). 
Se18.9 is a factor H binding protein that reduces deposition of C3b on the bacterial 
surface thus inhibiting phagocytosis (Tiwari et al., 2007). It shares very limited 
homology (20%) to the corresponding region of S. zooepidemicus. IdeE is one of two IgG 
endopeptidases of S. equi that shares homology to IdeZ (86%) of S. zooepidemicus and 
EndoS (70%) of S. pyogenes. IdeE is a Mac-1 (CD11b) homologue that reduces the 
bactericidal activity of equine neutrophils for S. equi. IdeE was shown to be expressed 
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during infection and to elicit strong and persistent serum and mucosal antibody 
responses. In addition, specific antibodies against IdeE were shown to neutralize its 
antiphagocytic activity (Timoney et al., 2008; Flock et al., 2012). Thus, inclusion of IdeE 
in a vaccine is potentially highly advantageous. Additionally, vaccination studies in 
horses with two multicomponent vaccines that differ only in the presence or absence of 
both IgG endopeptidases of S. equi, IdeE and IdeE2, demonstrated that specific 
antibodies to these proteins play a role in protection during convalescence. (Guss et al., 
2009). 
To test the immunogenic properties of this vaccine, we immunized Welsh ponies 
IM (n=10) or IN (n=2) with RacH/SeM/IdeE/Se18.9. Six ponies were immunized IM 
with empty RacH (WT) as controls.  Levels of serum antibody reactions to SeM, IdeE 
and Se18.9 pre and post vaccination were measured by ELISA and interpreted.  Sera of 
randomly selected ponies from each treatment group were tested for neutralizing 
antibodies to EHV-1. Sera from all ponies were tested for bactericidal activity.    
 
 5 
Chapter two - Literature Review  
2.1 Serological and physiological differentiation  
Schutz (1888), Poels (1888) and Sands and Jensen (1888) were among the first to 
describe isolation of streptococci from strangles cases. Schutz differentiated the pathogen 
of strangles from other streptococci by observing the failure of S. equi to grow in 
ordinary media, thus recognizing that it was different from the pathogen of pneumonia 
(Evans, 1936). In addition, he characterized the morphology and culture of the bacteria 
and described the symptoms and pathology of the infection in horses and experimentally 
inoculated white mice (Evans, 1936).  
The inability of S. equi to produce high titers of agglutinins in inoculated animals 
was first observed in 1902 (Piorkowski) and was subsequently confirmed by several 
investigators (Schnurer, Van Straaten, Stolpe, Pricolo). The protective effect of immune 
horse serum was demonstrated by Aronson (1903) and Pricolo (1910). 
The earliest attempt to differentiate streptococci through the use of blood agar is 
believed to have been made by Shottmuller in 1903, but it was not until 1919 that the 
reactions of streptococci on blood agar plates were first defined by J. H. Brown (1919). 
Differentiation of S. equi from other beta hemolytic streptococci of horses was 
attributed to Holth by Jensen (1911). He tested the reaction of isolated bacteria on 31 
different substrates and observed that the pathogen of strangles and the pathogen of 
pneumonia had different reaction patterns. Ogura (1929) applied Holth’s criteria to 201 
strains of beta hemolytic streptococci from horses. Use of 5 fermenting substrates 
(sucrose, salicin, sorbitol, lactose and trehalose) was found to divide these strains into 3 
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groups. The organisms which fermented sucrose and salicin were designated as S. equi. 
Organisms that fermented sucrose, salicin, sorbitol and lactose were designated as 
pyogenes A streptococci and organisms which fermented sucrose, salicin, trehalose and 
varied in ability to ferment lactose were designated pyogenes B streptococci. Ogura also 
noted that the organism designated S. equi was causative of strangles and that pyogenes 
A organisms were frequently and pyogenes B infrequently associated with suppurative 
infections. Additionally, he noted that pyogenes A and B streptococci could be cultured 
from the nasal mucosa of normal horses.  
Edwards (1932, 1933, 1935) and Dimock and Edwards (1933b) applied Ogura’s 
methods to study beta hemolytic Streptococcus from domestic animals and humans. He 
observed that pyogenes A streptococci were pathogenic for several animal species and 
the term Animal pyogenes, type A was then introduced by Edwards. Streptococcus 
zooepidemicus first used by Frost and Englebrecht (1936) was soon changed to 
Streptococcus pyogenes animalis by Seelemann (1942). 
Lancefield (1933), while determining a system to classify streptococci 
serologically, identified a cellular carbohydrate antigen common to S. equi and pyogenes 
A streptococci and which she termed group C. Subsequent serological studies on beta 
hemolytic streptococci by Edwards (1935) and Plummer (1935) confirmed Lancefield’s 
findings and reported additional group C strains including trehalose positive (pyogenes B 
streptococci) from humans and animals.  
Although S. equi was regarded as an equine pathogen, its virulence for white mice 
(Sand and Jensen, 1888; Schutz, 1888; Ogura, 1929), guinea pig (Poels and Nolen, Broq-
Rousseu 1907), rabbits (Poels), sparrows (Pricolo, 1910) and humans (Stolpe) was 
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reported. It was not until 1936 that Evans confirmed the specificity for horses after 
studying 600 strains of hemolytic streptococci from animal and human diseases. In 
addition, Evans (1936) reported that S. equi was highly virulent for mice and of low 
virulence for guinea pigs and rabbits. 
 
2.2 Nomenclature 
The term Streptococcus equi was first used by Sands and Jensen at their 1888 
description of the pathogen of strangles. Lancefield’s serotyping scheme was cited in 
Bergey’s manual of Determinative Bacteriology (Breed et al., 1948). The accepted 
descriptive term for S. equi was Streptococcus equi (Sands and Jensen, 1888); for 
pyogenes A streptococci was Streptococcus zooepidemicus (Frost and Engelbrecht, 1940) 
and for pyogenes B streptococci was Streptococcus equisimilis (Frost and Engelbrecht, 
1940).  
Farrow and Collins in 1984 demonstrated 92% DNA-DNA homology between S. 
equi and S. zooepidemicus and so they were reclassified as a single genomospecies. 
Streptococcus zooepidemicus was renamed S. equi subsp. zooepidemicus. Streptococcus 
equi was designated S. equi subsp. equi. (Euzeby, 2004) according to rule 46 of the 
International Code of Nomenclature (Lapage et al., 1992). 
Recent use of techniques in molecular biology in particular multi locus enzyme 
electrosphoresis (MLEE) and multi locus sequence typing (MLST) provided evidence 
that S. equi is a clonal derivative of S. zooepidemicus (Jorm et al., 1994; Webb et al., 
2008). Consequently, the correct nomenclature should be S. zooepidemicus subspecies 
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zooepidemicus and S. zooepidemicus subspecies equi. Unfortunately, errors in assigning 
the correct nomenclature/relationships of these organisms still occur in the contemporary 
literature. 
 
2.3 Ancestry and evolution 
The use of novel techniques in molecular biology to study the genetic structure of 
bacterial populations including DNA hybridization, MLEE and MLST provided evidence 
that S. equi is a clonal derivative of S. zooepidemicus (Jorm et al., 1994; Webb et al., 
2008).  The complete genome sequences of several of these streptococci are now 
available (S. equi 4047 (Holden et al, 2009); S. zooepidemicus ATCC35246, H70, and 
MGCS10565 (Beres et al, 2008; Holden, 2009; Ma et al, 2011) providing a basis for 
understanding evolution, niche adaptation, host specificity and virulence factors. 
Comparison of the genomes of Se4047 and SzH70 (Holden et al., 2009) identified recent 
genetic losses and gains showing that S. equi has passed through a genetic bottleneck 
during its evolution from an ancestral S. zooepidemicus. In addition, it demonstrated that 
the genome of S. equi lacks clustered regularly interspaced short palindromic repeats 
(CRISPR) locus which makes it prone to phage attack and invading DNA. As a result, 
Se4047 genome contains 4 different prophages and several novel genes that were 
acquired as cargo on bacteriophage (e.g. ICESe2, phospholipase A2 toxin slaA, 
superantigens SeeH, SeeI, SeeL, and SeeM) (Holden et al., 2009).  
Sequencing analysis of housekeeping genes of several isolates of both organisms 
revealed that S. equi strains are very closely related and are either ST-151 or ST- 179 
 
 9 
whereas the S. zooepidemicus population is highly diverse. To date, 308 STs 
(http://pubmlst.org/szooepidemicus/) of the latter have been identified. Analyses of STs 
suggest S. equi strains are almost clonal and most closely related to S. zooepidemicus ST-
101 (Webb et al., 2008). 
 
2.4 Niche adaptation 
S. zooepidemicus is a normal mucosal commensal found in the tonsillar tissue of 
the nasopharynx. In contrast, S. equi does not colonize mucosal or tonsillar tissue; instead 
it rapidly invades tonsil tissue and may then metastasize to draining lymph nodes 
(Timoney and Kumar; 2008). 
Analysis of S. zooepidemicus STs revealed that genetically similar clusters were 
commonly isolated from the same site of infection (either respiratory or reproductive 
tract) suggesting adaptation of certain STs to attachment to a set of host ligands specific 
to either respiratory or reproductive tissue (Holden et al., 2009). Interestingly, analysis of 
253 S. zooepidemicus isolates and 24 S. equi isolates revealed that S. equi is more likely 
to have evolved from a strain that caused uterine infection and abortion than from the 
respiratory tract. This suggests the ancestor of S. equi may have been better adapted to 
bind a set of host ligands different than ligands expressed in upper respiratory tissue. 
(Webb et al., 2008; Holden et al., 2009). Differences in sugar fermentation, commonly 
used as a tool to differentiate these organisms, may play a role in their ability to colonize 
different tissues. Evidence of the difference in adherence was demonstrated by comparing 
the genome of Se4047 and SzH70. Se4047 was found to lack functional homologues of 
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several sortase processed cell surface pili proteins of SzH70 that encode for adherence. S. 
equi expressed the accessory pilin, CNE protein. The repressor for cne was found to have 
a nonsense mutation suggesting deregulated pilus production and plays a role in the 
difference in adherence of S. equi and S. zooepidemicus (Holden et al., 2009).  
 
2.5 Biology 
Although, S. zooepidemicus and S. equi share over 98% DNA sequence homology 
they exhibit important differences in pathogenesis, host parasite interaction, and ability to 
activate immune responses effective in clearance. Additionally, despite their high genetic 
homology and similar protein profiles, infection by S. zooepidemicus does not confer 
protection against S. equi and vice versa.  
S. zooepidemicus is a mucosal commensal and opportunistic pathogen of several 
animal species including horses, cattle, goats, sheep, dogs, chickens, pigs, guinea pigs, 
dolphins and humans; and is capable of infecting different tissues types (e.g. lower 
respiratory and reproductive tracts). In contrast, S. equi typically does not colonize 
healthy horses, is highly host adapted, and its infection is restricted to the upper 
respiratory tract. Both are transmitted via direct or indirect contact and have a limited 
survival period outside of the host. 
S. equi typically infects young horses via the nose or mouth, rapidly penetrate 
naso- and oropharyngeal tonsils and is transported via afferent lymph vessels to regional 
lymph nodes. Although the incubation period varies from 3-6 days in the field, 
experimental studies demonstrated S. equi in lymph nodes 3 hours post infection 
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(Timoney and Kumar, 2008). Once in tonsils and lymphoid tissue, the bacteria evade the 
innate immune response, activating release of complement-derived chemotatic factors 
that results in a massive influx of neutrophils characteristic of the infection. In addition, 
high fever, nasal discharge, depression and anorexia occur. Abscesses usually drain either 
through the skin or into the guttural pouch. Infection is cleared following a course of 
approximately 14-21days. Complications are infrequent but include bastard strangles, 
purpura hemorrhagica, mastitis and laryngeal hemiplegia due to compression of the 
laryngeal nerve by an enlarged retropharyngeal lymph node. S. equi maintenance in 
Equidae is dependent on host infection. Purulent material containing S. equi that drains 
into the guttural pouch and/or cranial sinuses leads to empyema with eventual formation 
of chondroids. The organism survives for an extended period in empyemic guttural 
pouches, and is shed intermittently.    
Opportunistic infection of S. zooepidemicus in horses typically results in 
pneumonia, rhinitis, placentitis, endometritis, cervicitis, abortion, keratitis, mastitis, 
cellulitis and non-strangles lymph node abscessation. S. zooepidemicus has long been 
recognized as an important pathogen in equine reproduction (Dimock and Edwards, 
1928) and presently is the most frequently isolated pathogen associated with abortion in 
mares (Erol et al., 2012).  
The pathogenesis of S. zooepidemicus placentitis is not completely understood. 
The external genitalia of the mare and stallion are suggested as sources of the organism 
which opportunistically penetrate the cervix via natural or artificial insemination, 
iatrogenically or due to poor conformation of the internal and external genitalia of the 
mare causing infection.  
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Little is known about the pathogenesis of S. zooepidemicus in the lower 
respiratory tract of horses. The organism has been associated with lower airway disease 
of young horses with compromised or overwhelmed immune system due to stress 
(intense training, transportation) or secondary infection (Beech and Sweeney, 1991).  A 
specific clone from the tonsil has been shown to spread to the lungs resulting in severe 
damage to lung tissues (Oikawa et al., 1994). Although, pathology is caused by a single 
clone, these clones differ from one horse to another (Anzai et al., 2000).  
While isolates of S. zooepidemicus are highly variable (Moore and Bryans, 1969), 
isolates of S. equi are homogeneous genetically. However, sequence variation occurs in 
the N terminal region of SeM. Serologic studies have revealed many antigenically 
distinct strains of S. zooepidemicus.  
Horses and donkeys present different clinical signs in response to infection by S. 
equi and S. zooepidemicus. In donkeys, S. equi infection causes a more caseous form of 
lymphadenitis than seen in horses and respiratory S. zooepidemicus infection is 
characterized by a more severe bronchopneumonia. 
 
2.6 Virulence factors 
The molecular basis of S. equi and S. zooepidemicus pathogenesis involves 
complex interactions of several bacterial and host factors. Streptococci can efficiently 
alter (up- or down-regulate) the expression of their genes in response to different 
environmental factors. For instance, when cultured in media, expression of virulence 
associated genes of Streptococcus pneumoniae were found to be often “silent” but were 
 
 13 
induced during infection (Fu et al., 2013; Ogunniyi et al., 2002), the genome sequences 
of S. equi (Holden et al, 2009) and S. zooepidemicus (Beres et al, 2008; Holden, 20009; 
Zhe Ma et al, 2011) provid an array of information of many novel genes with putative 
roles in virulence. Previously, screening of an expression gene library of S. equi CF32 
with a pool of convalescent sera from horses resistant to infection by a SeM- mutant of S. 
equi revealed several immunoreactive plaques. Plasmids rescued from these phages were 
sequenced and compared with annotated genomic sequences of Se4047 and comparative 
sequence analysis identified novel immunoreactive proteins of S. equi (Timoney et al., 
2007). Additionally, comparative sequence analysis of the genes encoding homologous 
proteins in Se4047 and SzH70 highlighted differences between these organisms relevant 
to virulence (Holden et al. 2009).  
The following paragraphs review current information on virulence factors of S. 
equi and S. zooepidemicus.  
 
2.6.1 Capsule 
The mucoid appearance of colonies of S. equi and S. zooepidemicus is due to 
hyaluronic acid (HA). The presence of capsule on fresh isolates of both strains was first 
described by Ogura (1929), Seastone (1939b) and Bazeley and Battle (1940). Seastone 
observed a decrease and loss of capsule from cultures older than 6 hours.  
Capsular HA is an important virulence factor constitutively expressed in S. equi 
but not in S. zooepidemicus. Capsule expression by S. zooepidemicus is quickly lost 
following primary culture suggesting its expression is tightly controlled by host factors. 
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However, occurrences of atypical non-encapsulated strains of S. equi and strains of S. 
zooepidemicus that constitutively express capsule have been reported. Synthesis of 
capsule is encoded by the has operon. S. zooepidemicus contains the following genes 
hasA, hasB, hasC, glum and pgi, whereas these genes in S. equi are separated into 2 
operons one containing hasA, hasB, hasC and the other hasC, glum and pgi (Blank et al., 
2008). In addition, Holden et al (2009) reported that both Se4047 and SzH70 genomes 
contain 2 copies of hasC which encode UDP-glucose pysophosphorylasis. In SzH70, one 
copy of hasC (SZO17510) has been translocated to the opposite replichore by large 
reciprocal inversion. The small intra-replichore inversion in Se4047 between the 2 copies 
of hasC rearranges the genes associated with capsule in S. equi.  
Young cultures of S. equi that contained high levels of capsule were more 
resistant to phagocytosis than older cultures with decreased levels of capsule. 
Subsequently, in vitro and in vivo studies with S. equi decapsulated by hyaluronidases as 
well as non-encapsulated mutants of S. equi confirmed that virulence is directly related to 
the abundance of capsule (Timoney and Galan, 1985; Anzai et al, 1999).  
 The capsule provides a net negative charge and hydrophilicity to the bacterial 
surface and a reducing environment that protects the proteases and toxins of the bacteria. 
In the absence of capsule, surface exposed hydrophobic proteins lose conformation 
necessary for function (Timoney, 2010).  
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2.6.2 Hyaluronidase   
The role of hyaluronidase (HylC) as a virulence factor is questionable as this 
enzyme cleaves HA in the bacterial surface but also in host tissue where it may aid in 
spread of the bacteria. It is possible HA cleavage occurs at a slower rate than the 
production of capsule so that the antiphagocytic effect is not ablated (Starr and 
Engleberg, 2006). Additionally, the bacteria can use carbon rich molecules released from 
the reaction of HA cleavage as an energy source. In S. pneumoniae, hyaluronidase 
activity has a strong correlation with the capacity to induce meningitis and pneumonia 
(Hynes and Walton, 2000). 
HylC can also influence the colony appearance of HA producing streptococci. For 
instance, phage encoded hyaluronidase changes the mucoid phenotype of S. equi colony 
to matte at the end of the exponential phase of growth (Timoney et al., 1991). Unlike S. 
zooepidemicus, the gene for host encoded hyaluronidase in S. equi is inactivated by a 
frame-shift mutation and so capsule expression is abundant and constant (Holden et al., 
2009). Conversely, most but not all S. zooepidemicus produce an active hyaluronidase 
and colonies usually appear non-mucoid. 
 
2.6.3 Adhesins  
Adhesins bind to extracellular matrix in the host suggesting a role in attachment. 
FNE, a fibronectin binding protein of S. equi and its homologue in S. zooepidemicus, 
FNZ are encoded by almost identical genes. A single base deletion in fne results in loss of 
the C-terminal anchoring domain and so it is secreted, not anchored in S. equi (Lindmark 
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et al., 2001).  Loss of this adhesin from S. equi surface would be predicted to reduce its 
ability to adhere to tissue. Yi et al. (2012) observed reduced biofilm formation in the 
FNZ-negative mutant and its restoration to normal level with the reintroduction of fnz 
(L.Yi et al. 2012) which suggests that FNZ play an important role in biofilm formation in 
S. zooepidemicus strain ATCC35246 .  
CNE, an accessory pilin expressed by S. equi is a cell wall associated collagen 
binding protein encoded by FimI, which contains a TetR-like repressor with a nonsense 
mutation hypothetically resulting in deregulated production of elongated pilus. Fim I has 
been suggested to play a role in adherence of S. equi to tonsillar epithelium (Lannergard 
et al., 2003; Holden et al., 2009; Waller et al., 2011), but evidence of this, including 
microscopic studies, has not been forthcoming. Moreover, convalescent sera from S. equi 
infected horses have very low or absent levels of CNE specific antibody (Timoney et al., 
2007). This suggests FimI pili are not expressed by S. equi.  
SFS inhibits binding between fibronectin and collagen in a concentration 
dependent manner. It was present in all of 50 S. equi and 41 of 48 S. zooepidemicus 
studied (Lindmark and Guss, 1999).  
 
2.6.4 Antiphagocytic SeM  
The M-like protein of S. equi, SeM, as well as its homologue in S. zooepidemicus, 
SzM, are fibrillar surfaced anchored proteins. SeM is a major virulence factor by virtue of 
its ability to bind fibrinogen and reduce C3b deposition on the cell surface, thus 
inhibiting phagocytosis by neutrophils (Boschwitz and Timoney, 1994; Meehan et al., 
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2001). SeM binds fibrinogen through its unique N-terminal third and binds 
immunoglobulins (IgG 4 and 7) through its central region (C-terminal region), SeM 
shares limited homology with SzM. SeM and SzM are highly immunogenic and 
antibodies raised against them have robust opsonic properties. Vaccination of mice with 
SeM or SzM protected against experimental challenge with S. equi or homologous S. 
zooepidemicus, respectively. Subcutaneous vaccination of horses with recombinant SeM 
and other proteins was not protective (Timoney et al., 2007). SzM is highly variable 
among S. zooepidemicus strains, sharing only 20 to 55% homology. Therefore 
vaccination with SzM may not protect against a diverse population of S. zooepidemicus.  
SzPSe is a fibrinogen-binding protein with limited antiphagocytic properties. Its 
gene is located adjacent to genes for FimI. While SzPSe is highly conserved among S. 
equi (Ijaz et al., 2011), its homologue in S. zooepidemicus, SzP, is highly variable.  
Antibodies raised against SzPSe are cross reactive with SzP. Recent work by Zhe Ma et 
al. (2012) suggests that SzP inhibits host immune response by down regulating Toll-like 
receptor 6 (TLR6) thus reducing pro-inflammatory cytokines. In addition, SzP was found 
to affect multiple signal transduction pathways. 
 
2.6.5 Streptolysin S 
Streptolysin S, first identified in S. pyogenes (Todd, 1938; Weld, 1934), is a 
bacteriocin-like cytotoxin responsible for the characteristic beta hemolysis of S. equi and 
S. zooepidemicus (Flanagan et al., 1998). Binding of the Streptolysin S complex to 
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erythrocyte results in formation of a transmembrane pore and osmotic lysis. (Flanagan et 
al., 1998, Carr et al., 2001).   
 
2.6.6 Streptokinase 
Streptokinase (SKC), an important virulence factor, is a secreted enzyme that 
cleaves plasminogen into active plasmin thus causing dissolution of the fibrin barrier and 
facilitating tissue invasion. SKC is highly conserved among S. equi and S. zooepidemicus 
sharing 99% DNA homology.  
 
2.6.7 IgG Fc-receptor proteins  
S. equi proteins IdeE and IdeE2 and their respective homologues in S. 
zooepidemicus, IdeZ and IdeZ2; cleave IgG. Additionally, IdeE2 promotes platelet 
aggregation (Muthupalani, 2005), is more efficient than IdeE in cleaving IgG and 
together with IdeZ2 has high substrate specificity for horse IgG (Hulting et al., 2009). 
IdeE2 is among the earliest antigens to be recognized and therefore is suggested to play a 
role in protective immunity. As expected, the ideE2 gene is highly conserved while ideZ2 
is variable. 
In vitro studies demonstrated that IdeE a Mac-1 (CD11b) homologue reduces the 
bactericidal activity of equine neutrophils for S. equi and this antiphagocytic activity is 
neutralized by specific antibodies (Timoney et al., 2008). Vaccination studies with two 
multicomponent vaccines that differ only in the presence or absence of both, IdeE and 
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IdeE2, demonstrated that the convalescent specific antibodies play a role in protection 
against S. equi (Guss et al., 2009). 
 
2.6.8 Superantigens (SePE-H, I, L and M) 
The genes for superantigens (sAgs) SePE-H, SePE-I are absent from S. 
zooepidemicus while SePE-L and SePE-M occur in some S. zooepidemicus strains. Phage 
associated transfer of these genes has been suggested to have played an important role in 
the evolution of S. equi (Artiushin et al., 2002; Holden et al., 2009). 
sAgs are mitogenic for equine peripheral blood mononuclear cells (PBMC) and 
are pyrogenic in rabbits (Artiushin et al., 2002; Anzai et al., 1999; Alouf et al, 1991). 
These proteins bind to MHC class II antigens along with T cell receptor activating non-
specific T cells. Polyclonal T cell activation misdirects the immune response. Subsequent 
release of numerous pro-inflammatory cytokines triggers the characteristic acute phase 
response of strangles (e.g. fever, neutrophilia and hyperfibrinogenemia).   
Identification of sAgs in S. zooepidemicus in greater frequency in isolates from 
lymph node abscesses suggests sAgs may enhance the ability of S. zooepidemicus to 
metastasize to lymph nodes (Paillot et al., 2010; Waller et al., 2011). 
 
2.6.9 Peptidoglycan  
Peptidoglycan is a potent activator of the alternative complement pathway, 
causing release of chemotatic factors (C3a, C5a) and pyrogenic cytokines (IL-6, TNF). 
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Karakawa and Krausse (1966) demonstrated antibody responses to peptidoglycan of 
group A and C streptococci by precipitation and immunoelectrophoretic tests. Mukhtar 
and Timoney (1988) demonstrated a strong chemotatic response of equine 
polymorphonuclear leucocytes to peptidoglycan incubated with equine plasma as a 
complement source.  
 
2.7 Proteins expressed from a S. equi gene library 
 
2.7.1 Se18.9 
Se18.9 is a factor H binding protein that reduces deposition of C3b on the 
bacterial surface thus inhibiting phagocytosis (Tiwari et al., 2007). Although homology 
to gene sequences in most S. zooepidemicus strains is only 20%, a recent study found 
Se18.9 was produced by 1 of 140 S. zooepidemicus and by all 26 S. equi (Holden et al., 
2009).  
 
2.7.2 SeCEP 
A surface proteinase that cleaves CXC chemokines, including interleukin 8 (IL-8)  
and thus interfering with recruitment of neutrophils and enhancing evasion of the 
pathogen (Edwards et al. 2005; Turner et al., 2009, Waller et al., 2011). It shares 98% 
DNA homology with S. zooepidemicus ScpC. 
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2.7.3 Se110.0 
A surface protein of S. equi with unknown function, Se110.0 shares 86% DNA 
homology with S. zooepidemicus H70 (Timoney et al., 2007). 
 
2.7.4 Se75.3 
A multiligand binding protein with putative regulatory function, Se75.3 shares 
96% DNA homology with S. zooepidemicus H70 (Timoney et al., 2007). 
 
2.7.5 Se46.8 
Se46.8 is a proline-rich, peptidoglycan-anchored, mucosally immunogenic protein 
of S. equi that binds to equine fibrinogen and has a weak affinity for fibronectin. It’s role 
in resistance to infection is not yet known. It shares 74% DNA homology with S. 
zooepidemicus H70 (Timoney et al., 2007). 
 
2.7.6 Se42.0 
A peptide methionine sulfoxide reductase (MSR) of S. equi, Se42.0 shares 99.7% 
amino acid identity with S. zooepidemicus H70 (Timoney et al., 2007). 
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2.8 Proteins expressed from a gene library of S. zooepidemicus NC78 
 
2.8.1 MAP 
A membrane anchored protein highly conserved among S. zooepidemicus strains 
and with high DNA homology (95%) to S. equi. 
2.8.2 FSR 
A putative ferric siderophore receptor not expressed in S. equi and highly 
conserved among S. zooepidemicus strains (96-100% homology). 
 
2.8.3 ScpC 
An IL-8 protease homologue to SeCEP of S. equi and Spy0416 of S. pyogenes. 
It’s conserved among S. zooepidemicus strains. Spy0416 belongs to a family of calcium 
dependEnt streptococcal serine proteases that promote bacterial dissemination in the 
respiratory tract (Kurupati et al., 2010).  
 
2.8.4 Sz115 
A putative secreted protein with mucinase activity and high homology shared by 
S. equi and S. zooepidemicus strains (98-100%). 
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2.8.5 SzMAC 
SzMAC is a MAC family protein highly variable among S. zooepidemicus strains 
(only 28-40% DNA homology) and sharing 40% homology with S. equi protein IdeE. 
 
2.8.6 INLA 
A cell surface anchored protein highly conserved among S. zooepidemicus and 
absent from S. equi. 
 
2.8.7 OppA 
An extracellular oligopeptide binding protein highly conserved among S. 
zooepidemicus (99-100% homology) and S. equi (99%). 
 
2.8.8 Enolase 
Enolase, a phosphopyruvate hydratase is highly conserved among S. 
zooepidemicus and S. equi (99-100%). 
 
2.8.9 AhpC 
An alkyl hydroperoxide reductase that is highly conserved among S. 
zooepidemicus (99-100% homology)  
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2.8.10 GAPDH 
 Glyceraldehyde-3-phosphate dehydrogenase is highly conserved among S. 
zooepidemicus and S. equi (99-100% homology). 
 
2.9 Immunity and vaccines 
The majority of horses naturally infected with S. equi develop a solid and 
persistent (>5 years) immunity to strangles, indicating that it is biologically possible to 
achieve strong long-lasting immunity against the pathogen. Weanlings recovered from 
strangles had a high level of resistance to subsequent commingling exposure to strangles 
cases (Galan and Timoney, 1985).  
 
2.10 Humoral antibody responses 
The protective effect of immune horse serum was first demonstrated by Aronson 
(1903) and Pricolo (1910).  Subsequently, it was noted that approximately 75% of horses 
that recover from strangles develop a solid long-lasting immunity to re-infection (Todd, 
1910; Galan and Timoney, 1985; Hamlen et al, 1994). Respiratory infection by S. 
zooepidemicus appears to protect horses against reinfection but infection by S. 
zooepidemicus does not confer protection against S. equi and vice versa (Bazeley, 1942). 
Convalescent horses produce strong serum antibody (IgGb) response to S. equi 
proteins SeM, IdeE2, Se46.8, Se45.5 and Se42.0 (Timoney et al, 2010) and sero-
conversion was shown to occur to IdeE2 and Se18.9 following reinfection of resistant 
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animals, and to a lesser extent to Se46.8, Se75.3 and Se42.0 (Muthupalani, 2005). 
Interestingly, vaccination of horses with multicomponent vaccines with several 
combinations of surface exposed or secreted recombinant proteins although inducing 
strong specific serum antibody responses, did not induce long-lasting protection.  
 
2.10.1 S. equi  
Early vaccination studies with S. equi began in 1940s in Australia. Mice and 
horses vaccinated with heat inactivated (56 °C) or formalinized S. equi in early phase of 
growth and mice that received adoptive transfer of strangles convalescent horse sera were 
protected against experimental challenge (Bazeley et al., 1940a, 1940b, 1942a, 1942b). 
Adverse reactions from vaccination of horses with these bacterins (eg., injection site 
abscess, muscle soreness associated with vaccination) resulted in further investigations of 
protein rich vaccines prepared by acid or enzymatic (mutanolysin) extraction of S. equi 
that lack bacterial irritants responsible for adverse reactions (Hoffman et al., 1991; 
Timoney, 2004).   
Conventional vaccines containing bacterial extracts (e.g., Strepgard, Intervet; 
Strepvax II, Boehringer Ingelheim; Equivac S, Pfizer) generated potent serum antibody 
responses and reduced clinical signs of infection but failed to stimulate mucosal 
antibodies and strong protective immunity (Timoney and Eggers, 1985; Sheoran et al., 
1997). Resistance of horses to S. equi reinfection was associated with both serum and 
mucosal antibody responses (Hamlen et al., 1994) and local nasopharyngeal mucosal 
response was postulated to play important role in protection against S. equi infection. 
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In an effort to stimulate both mucosal and serum antibody responses against S. 
equi, intranasal live attenuated vaccines designed to mimic natural infection were 
developed and commercialized (Pinnacle I.N., Fort Dodge; Pinnacle HasNeg, Fort 
Dodge, Equilis StrepE, Intervet). Although live attenuated vaccines protected against 
experimental challenge, during natural infection they lacked efficacy or induced short-
lived immunity. In addition, some caused severe adverse effects due to residual virulence.  
Several different antigens and/or combinations of antigens and delivery methods 
have been investigated. Vaccination studies with recombinant proteins (eg. SeM, 
hyaluronate associated protein), although able to elicit increased antibody levels and 
protect mice from experimental challenge, failed to protect horses (Timoney et al, 1997; 
Sheoran et al. 2002; Chanter et al., 1999; Waller et al. 2007).  
Vaccination studies with multi-component subunit vaccines have demonstrated 
strong serum antibody response, partial protection and no adverse effects. Vaccination of 
Welsh mountain ponies with a multi-component subunit vaccine composed of 
recombinant CNE, IdeE, EAG and SclC demonstrated reduced clinical signs and reduced 
bacterial shedding against challenge with S. equi (Waller et al., 2007).  
Two multi-component subunit vaccines composed of surface exposed or secreted 
proteins of S. equi identified in an expression gene library with sera from resistant horses 
were used to vaccinate ponies subcutaneously. Vaccine 1 or linkage group 1 vaccine was 
composed of genes for SzPSe, CNE, Se51.9, IdeE2, Se46.8 linked together and vaccine 2 
was composed of 4 proteins recognized during infection by a S. equi SeM- mutant but not 
during infection by S. zooepidemicus 631 (IdeE2, Se75.3, Se42.0, Se110.0) and the 
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addition of SeM and Se18.9.  Both vaccines elicited strong serum antibody levels to each 
component but failed to protect against comingling challenge with SeCF32 (Timoney et 
al., 2007). 
Vaccination of horses with a multi-component vaccine, Septavacc, composed of 
EAG, CNE, SclC, SEQ0256, SEQ0402, IdeE and IdeE2 protected 6 of 7 horses against 
experimental challenge with cultured bacteria. Additionally, when IdeE and IdeE2 were 
omitted from this vaccine, only partial protection was achieved highlighting the important 
role of both antigens in establishing protection (Guss et al., 2009).  
 
2.10.2 S. zooepidemicus  
The high diversity of the S. zooepidemicus population adds complexity to 
development of an efficient vaccine with broad range. Vaccines protective against 
different strains of S. zooepidemicus will require antigens that stimulate cross protective 
antibodies among strains.   
Immunization of mares with enzymatic extracts of a pathogenic strain recovered 
from an abortion case (Sz90 3864B) via combined intrauterine (IU) and intramuscular 
(IM) routes resulted in reduced inflammation and local infection in response to 
subsequent challenge, following challenge were with a homologous strain (Widders et 
al., 1995). In addition, IM administration caused severe side effects including edema, 
muscular stiffness and abscess formation. Live attenuated Salmonella enteric serovar 
Typhimurium MGN707 expressing SzP from Sz-MB9 isolated from a mare with metritis 
was used to vaccinate mares intranasally and was successful in reducing the number of S. 
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zooepidemicus in the uterus after intrauterine challenge with homologous S. 
zooepidemicus (Causey et al., 2010). Protection was also achieved in mice immunized 
with SzP vectored by swinepox virus followed by challenge with Sz ATCC 35246 a 
virulent Chinese porcine strain, (Lin et al., 2011).  Vaccination of mice with Sz ATCC 
35246 attenuated by deletion of SzP was also protective against challenge with the 
homologous virulent strain (Hong-Jie et al., 2009) indicating presence of protective 
antigens additional to SzP.  
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Chapter three - Material and Methods 
3.1 Bacterial strains and culture 
Streptococcus equi CF32 from a strangles case in New York, USA (1981) and 
Streptococcus zooepidemicus NC78 from an epizootic of equine respiratory disease in 
New Caledonia (1997-98) were cultured overnight at 37ºC in Todd Hewitt Broth (THB) 
+ 0.2% yeast extract.  
 
3.2 Production of recombinant proteins and polyclonal sera 
Recombinant proteins of SeCF32 and SzNC78 identified with equine 
convalescent sera in genomic DNA libraries were produced as described elsewhere 
(Timoney et al., 2007; Velineni and Timoney, 2013). Briefly, open reading frames 
encoding targeted proteins without signal sequences were amplified by PCR using 
chromosomal DNA of either SeCF32 or SzNC78 as template and the amplicons were 
inserted into pET-15b or pRSET-A and transformed into E. coli BL21 (DE3). Purity of 
His-tag fusion proteins was checked by SDS-PAGE. 
New Zealand rabbits and yearling goats were used for raising polyclonal antisera 
against Se and Sz proteins, respectively.  Polyclonal antisera were raised by subcutaneous 
administration of 150 μg of each purified recombinant antigen separately with either 33% 
Alhydrogel or QuilA (10 mg/ml) as an adjuvant. Booster injections containing 100 μg of 
recombinant protein were administered 14 and 28 days after the primary immunization. 
Sera were obtained 2 weeks after the last booster dose. Antibody titers in sera collected 
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on day 0, 28 and 42 were determined by ELISA on 96 well plates coated with each 
recombinant protein. Tables 3.2.1 and 3.2.2 summarize information about recombinant 
proteins. 
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TABLE 1 - TABLE 3.2.1: Proteins of S. equi CF32, accession numbers, locus tags and 
percentage sequence homology with S. zooepidemicus H70. 
Se  protein Acc. # Locus tag % homology 
SeM-N2 - SEQ2017 0   
SzPSe U73162 SEQ0933 88 
Se110.0 AY137519 SEQ1116 86 
Se75.3 AY137528 SEQ2190 96 
Se46.8 AF521600 SEQ0939 74 
IdeE2 FJ792821 SEQ0938 70 
Se42.0 AY137521 SEQ0589 99.7 
Se18.9 DQ068464 SEQ0235 20 
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TABLE 2 - TABLE 3.2.2: Proteins of S. zooepidemicus NC78 (Sz) , accession numbers, 
locus tags, homologues in SeCF32 and variability among S. zooepidemicus strains. 
Proteins of 
Acc. # Locus tag 
% 
homology 
with Se 
Orthologue 
in Se 
% 
homology 
among Sz SzNC78 
Eno CAW99637 SZO11840 100 SEQ0898 100 
SzM YP_002743751 SZO01900 23 SEQ2017 20-55 
OppA YP_002743835 SZO02770 99 SEQ1919 99-100 
MAP YP_002745205   SZO16930 95 SEQ0339 92-100 
FSR YP_002745120   SZO16070 - Pseudogene 96-100 
INLA YP_002744383    SZO08560 - Absent 90-100 
Sz115 YP_002744189 SZO06450 97 SEQ1505 98-100 
SzMAC YP_002744674 SZO11480 39 SEQ0938 28-40 
ScpC YP_002744998 SZO14810 98 SEQ0563 98-100 
SzP YP_002744679 SZO11530 88 SEQ0933 49-90 
SKC YP_002743754 SZO01930 99 SEQ2014 90-100 
AhpC YP_002743680 SZO01180 99 SEQ0132 100 
GAPDH YP_002745200 SZO16880 99 SEQ0345 99-100 
HylC YP_002744212 SZO06680 - Pseudogene 96-100 
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3.3 Determination of antibody levels  
Antibody levels in sera were examined by ELISA using 96 well flat bottomed 
polystyrene microtiter plates (Costar, Corning, NY) coated in triplicate with 1 µg per well 
of each recombinant protein separately except for SeM-N2 (aa37-190, 0.1 µg/well) in 
100 µl of coating buffer (0.1M carbonate bicarbonate, pH 9.2) overnight at 4ºC. Plates 
were incubated overnight at 4°C, washed with PBS-Tween, blocked with 4% skim milk 
and incubated at 37°C for 1 hour with triplicate aliquots of sera at 1:100 dilutions. 
Reactions were developed with horseradish peroxidase (HRP) conjugated Protein G 
(Sigma-Aldrich) at a concentration of 1:8000 and O-phenylenediamine (OPD) substrate 
(Sigma-Aldrich). Reactions were recorded as optical densities (OD) measured at 490nm. 
SeM-N2 recombinant protein used in the ELISA is the N-terminus of SeM unique to S. 
equi (aa37-190).  
 
3.4 Convalescent sera 
Pre- and post-infection strangles sera were from 9 Welsh ponies raised on the 
University of Kentucky farm and inoculated intranasally with 3 x 108 CFU of SeCF32. 
Ponies developed typical strangles including fever of 103°F or higher, nasal discharge, 
lymph node abscesses and detection of S. equi in cultures of nasal swabs. Sera from 7 
donkeys that recovered from strangles and developed Sz pneumonia after 6 months 
following experimental challenge with equine Influenza virus were also included.  
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Sera were from weanling and adult horses with rhinitis, bronchitis and pneumonia 
associated with S. zooepidemicus.  Clinical evidence of respiratory disease included nasal 
discharge, cough, fever, lung consolidation. Large numbers of S. zooepidemicus in 
cultures of nasal swabs and nasopharyngeal lavages established an etiological association 
with this organism. 
Sera from 5 pregnant mares with Sz placentitis were obtained following 
experimental inoculation intracervically of 5 x 106 CFU of an overnight culture of a strain 
of S. zooepidemicus from a case of placentitis. Uterine infection was confirmed by 
ultrasound scan (increased combined thickness of the uterus and placenta (CTUP)), 
bacterial culture and histopathological examination of the placenta. 
A positive control for antibody to S. equi proteins consisted of a pool of sera from 
3 cases of strangles (Pool). A positive control serum for S. zooepidemicus was obtained 
from a horse (631) that developed severe peritonitis caused by S. zooepidemicus 631. 
Negative control sera for S. equi and S. zooepidemicus antibody were obtained from 2 
foals with no history of streptococcal disease (Foal and Lyons3). Table 3.4.1 summarizes 
information about horses and sera. 
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TABLE 3 - TABLE 3.4.1: SUMMARY OF DATA FOR SERA SELECTED FOR 
COMPARISON OF REACTIVITIES WITH PROTEINS OF S. EQUI (SE) AND S. 
ZOOEPIDEMICUS (SZ). 
Serum 
Identification 
Day 
History 
Pre 
serum 
Post 
serum 
Horse and Pony  
4, 49, 53, 54, 56, 59, 
77, 912, 9801-9810, 
9812 
1 95 Cough, nasal discharge, pneumonia, on days 60-80. Sz isolated from all cases.   
Horse  
2, 6-10, 59, Prince, 
SF 
1 43-56 
Inoculated with S. equi CF32 (3 x 108 
CFU) intranasally on day 1. Strangles 
developed over following 12 days. 
Horse  
D17, L131, K141, 
643, 9907 
1 10-27 
Intrauterine inoculation of 5 x 106 CFU 
with S. zooepidemicus from a case of 
placentitis. Sera were collected 
11(L131) to 28 (K141) days after 
inoculation.   
Donkey  
Coco, Jennie, Lais, 
Millie, Rosie, 
Shaggy, Sheila 
1 52 
Donkey had clinical strangles in Spring 
1993. Developed pneumonia associated 
with S. zooepidemicus in Fall of 1993 
following experimental inoculation with 
equine influenza virus (KY/1/91) 
Control Pony 
631 (+ Sz control)     
S. zooepidemicus 631 isolated from case 
of peritonitis in pony housed all its life 
in isolation.  
Se Pool (+ Se 
control)     
 Pool of convalescent sera from cases of 
strangles  
Lyons3 (- Se and Sz 
control)     
Serum from weanling horses with no 
history of clinical Se or Se 
Foal (- Se and Sz 
control)     
Serum from  4 months old foal with no 
history of clinical Se or Se 
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3.5 Statistical analysis 
An increase in antibody level was arbitrarily defined as a value for post infection 
serum that was ≥ twice the value for the pre-serum. Mean and standard errors of the mean 
were calculated for OD490nm values of pre and post sera and a Student’s t-test was used to 
compare differences between mean OD values of pre and post sera for each protein.  
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Chapter four - Results 
4.1 Selection of proteins 
 Fourteen and 8 immunoreactive recombinant proteins from SzNC78 and SeCF32, 
respectively were selected for ELISA testing based on putative function, potential 
significance as virulence factors and surface expression or secretion. Proteins and 
percentage DNA homologies shared among S. equi and S. zooepidemicus are listed on 
Tables 4.2.1 and 4.2.2. 
 
4.2 Reactivity of recombinant proteins with serum antibody in horses recently 
recovered from strangles, S. zooepidemicus respiratory infection or 
placentitis. 
Pre- and post-sera (Table 3.4.1) were tested by ELISA for IgG reactive with S. 
equi and S. zooepidemicus proteins (Appendix tables A, B, C). OD490 nm values for post-
serum that were ≥ twice the value of pre -serum were regarded as increased based on 
previous challenge studies performed in our laboratory.  
Experimentally induced placentitis did not produce increase in ELISA ODs to S. 
equi proteins and only 1 of 5 mares tested presented increased OD to MAP (Appendix 
table B). Differences in OD’s of pre- and post-sera from donkeys were not significant (p= 
0.05) (Figure 4.2.B). 
The percentage of sera with increased OD values (OD490 nm ≥ 2 x) was calculated 
for each animal group (Tables 4.2.1 and 4.2.2) and results for respiratory S. 
zooepidemicus infection and strangles groups were plotted for comparison (Figure 4.2.A). 
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Serum antibody responses following strangles were stronger and involved more proteins 
than following respiratory S. zooepidemicus infection.  
All strangles convalescent sera reacted with at least 50% of S. equi proteins 
whereas the majority (56%) of sera from cases of S. zooepidemicus respiratory infection 
were unreactive with S. equi proteins.  Post strangles sera showed increased ODs to S. 
equi proteins IdeE2 (100%), Se75.3 (89%), Se46.6 (89%), Se18.9 (89%), Se110.0 (67%),  
andSePSe (11%). Sera from cases of respiratory S. zooepidemicus showed increases  to 
Se110.0 (50%), SePSe (22%), Se18.9 (11%) and IdeE2 (6%).  
The majority of sera from strangles had increased OD to Sz proteins OppA (56%) 
and SzMAC (56%). No increase in ODs to ENO, FSR, INLA, Sz115.0 and ScPC was 
observed. Reactions of sera from cases of S. zooepidemicus respiratory infection with S. 
zooepidemicus proteins varied greatly and involved all proteins except AhpC and 
GAPDH. Greater percentages of sera showed increased ODs to ScPC (50%) and HylC 
(56%). Other increased reactions included SKC (39%), MAP (33%), Sz115.0 (33%), SzP 
(33%), OppA (28%), FSR (28%), SzMAC (17%), SzM (11%), INLA (11%) and ENO 
(6%).  
Serum antibody responses of horses were quantitatively and qualitatively much 
greater following recovery from strangles than from S. zooepidemicus pneumonia. All 
strangles sera showed increased ODs to at least half of the S. equi proteins and the 
majority reacted with at least one S. zooepidemicus protein. On the other hand, sera from 
only 4 of 18 cases of respiratory S. zooepidemicus showed increased OD’s to at least half 
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of the S. zooepidemicus proteins. This group showed increased OD’s to less than half of 
the S. equi proteins.  
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 TABLE 4 - TABLE 4.2.1: Percentages of convalescent sera from cases of 
strangles (Se) and S. zooepidemicus (Sz) respiratory infection and placentitis with 
increased reactivity (≥ 2 x) OD490 nm to S. equi proteins. Sera were diluted 
1:100. 
Se 
Protein 
Sz Sera Se Sera 
Total 
Respiratory Placentitis Strangles 
# 
increased % 
# 
increased % 
# 
increased % 
# 
increased % 
SeM-N2 0/18 0 0/5 0 0/9 0 0/32 0 
SzPSe 4/18 22 0/5 0 1/9 11 5/32 16 
Se110.0 9/18 50 0/5 0 6/9 67 15/32 47 
Se75.3 0/18 0 0/5 0 8/9 89 8/32 25 
Se46.5 0/18 0 0/5 0 8/9 89 8/32 25 
IdeE2 0/18 0 0/5 0 9/9 100 9/32 28 
Se42.0 0/18 0 0/5 0 6/9 67 6/32 19 
Se18.9 2/18 11 0/5 0 8/9 89 10/32 31 
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TABLE 5 - TABLE 4.2.2: Percentages of convalescent sera from cases of strangles (Se) 
and S. zooepidemicus (Sz) respiratory infection and placentitis with increased reactivity 
(≥ 2 x) OD490 nm to S. zooepidemicus proteins. Sera were diluted 1:100. 
 
Sz Protein 
Sz Sera Se Sera TOTAL 
Respiratory Placentitis Strangles 
# % 
# 
increased % 
# 
increased % 
# 
increased % 
Enolase 1/18 6 0/5 0 0/9 0 1/32 3 
SzM 2/18 11 0/5 0 1/9 11 3/32 9 
OppA 5/18 28 0/5 0 5/9 56 10/32 31 
MAP 6/18 33 1/5 20 3/9 33 10/32 31 
FSR 5/18 28 0/5 0 0/9 0 5/32 16 
INLA 2/18 11 0/5 0 0/9 0 2/32 6 
Sz115 6/18 33 0/5 0 3/9 33 9/32 28 
SzMAC 3/18 17 0/5 0 5/9 56 8/32 25 
ScpC 9/18 50 0/5 0 0/9 0 9/32 28 
SzP 6/18 33 0/5 0 1/9 11 7/32 22 
STK 7/18 39 0/5 0 1/9 11 8/32 25 
AhpC 0/18 0 0/5 0 2/9 22 2/32 6 
GAPDH 0/18 0 0/5 0 2/9 22 2/32 6 
HylC 10/18 56 0/5 0 - - - - 
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FIGURE 1 -   FIGURE 4.2.A: Percentages of convalescent sera from cases of strangles 
(Se) and respiratory disease (Sz) with increased (≥ 2 x) reactivity to S. zooepidemicus and 
S. equi proteins. Sera were diluted 1:100. S. zooepidemicus proteins were from NC78. 
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FIGURE 2 -   FIGURE 4.2.B: Means and standard deviations of ELISA OD490 nm 
values for sera of donkeys recovered from strangles (9/21/1993) and following S. 
zooepidemicus pneumonia (11/11/93). S. zooepidemicus proteins were from SzNC78. 
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Chapter five - Discussion and Conclusions 
The goal of this work was to compare antibody specificities of sera from horses 
following strangles with specificities generated by respiratory infection due to S. 
zooepidemicus and identify differences in pathogenesis of the diseases caused by the 
almost identical S zooepidemicus and equi as well as identify proteins that could be used 
to measure antibody responses specific to each organism. 
Infections by S. equi induce a strong long-lived protective immunity (Todd, 1910; 
Galan and Timoney, 1985; Hamlen et al, 1994; Timoney et al., 2007) and respiratory 
infection by S. zooepidemicus appears to protect horses from reinfection (Hoffman et. al, 
1993). However, infections by these organisms are not cross protective (Bazeley, 1942). 
Therefore, antibodies against proteins uniquely recognized during strangles or respiratory 
S. zooepidemicus infection are predicted to play an important role in protective immunity 
against the corresponding infection.  
 
5.1 Immune response to S. equi proteins  
S. equi proteins that reacted almost exclusively with strangles sera included 
IdeE2, Se75.3, Se46.6, Se18.9 and Se 42.0.  
Se18.9 is a factor H binding protein with anti-phagocytic properties. Increased 
bactericidal activity was noted in vitro in the presence of specific antiserum (Tiwari et al., 
2007). se18.9 shares only 20% DNA homology to counterpart  in  S. zooepidemicus and 
therefore is a good candidate protein to differentiate both infections using an ELISA. 
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Other good candidates include IdeE2, an IgG endopeptidase and Se46.8, a proline rich 
protein with numerous PEPK repeats. Genes encoding IdeE2 and Se46.8 are linked in the 
same operon, suggesting a functional virulence unit (Timoney et al., 2007) and so related 
immune responses to both are not surprising. They share 70% (idee2) and 74% (se46.8) 
DNA homology with their counterparts in S. zooepidemicus, respectively and were 
previously shown to be among the most consistently recognized proteins of S. equi 
following a 28 weeks experimental challenge (Muthupalani, 2005). 
The presence of antibodies specific for Se75.3, a multiligand binding protein with 
putative regulatory function and for Se42.0, a peptide methionine sulfoxide reductase,  
with convalescent S. equi but not S. zooepidemicus sera is interesting since their genes are 
highly conserved between S. equi and S. zooepidemicus (96% and 99.7% DNA 
homology, respectively). Either the proteins are not expressed by S. zooepidemicus 
during respiratory infection or are not processed for immune response.Alternatively, 
antibodies against S. equi are unable to bind to the S. zooepidemicus homologue.   
Serum antibody to Se110.0 was increased in 67% of strangles cases and 50% of 
cases of respiratory S. zooepidemicus. se110.0 shares 86% DNA homology with its 
counterpart in S. zooepidemicus NC78. 
Although antibody reactions post strangles for SzPSe were greater than the 
positive control as well as the corresponding pre-sera, ODs were not ≥ 2 x higher than the 
corresponding pre-sera. This could be due to the high background reactivity to SzPSe 
observed in most serua, likely due to cross reactivity of antibodies to SzP of strains of S. 
zooepidemicus that colonized tonsils.  
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5.2 Immune response to S. zooepidemicus proteins 
The majority of sera from respiratory S. zooepidemicus cases (56%) reacted with 
HylC. The gene for HylC is inactivated in S. equi hence strangles sera were not tested for 
antibodies to HylC. Hyaluronidase is a virulence factor of various microorganisms (eg. 
Streptocuccus pneumoniae, Candida albicans, Clostridium difficile, Staphylococcus 
aureus), but its role in protective immunity has not yet been elucidated.  
Antibody specific for ScpC was increased in 50% of sera from respiratory S. 
zooepidemicus cases, but not in strangles sera. Backgroud levels to ScpC were high in all 
serum groups except the respiratory S. zooepidemicus group. Background reactivity could 
be explained by cross-reactivity since scpc SzNC78 shares 98% DNA homology with S. 
equi secep.  
SzMAC and OppA specific antibodies were more likely to be elevated in serum 
from cases of strangles (56%) than from cases of S. zooepidemicus respiratory infection 
(17% and 28%, respectively). oppa in S. equi and S. zooepidemicus share high DNA 
homology (99%) and so antibodies elicited by S. zooepidemicus or S. equi will be 
crossreactive. szmac shares only 39% DNA homology with semac and is highly variable 
among S. zooepidemicus.  
Only 11% and 33% of sera from cases of respiratory S. zooepidemicus reacted 
with SzNC78’s SzM and SzP, respectively. Both proteins were expected to be highly 
variable in the isolates responsible for respiratory S. zooepidemicus infections and likely 
accounted for the limited antibody reactivity observed.   
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5.3 Background reactivity  
High background antibody to SzPSe was observed in sera from all animal groups 
except the placentitis group. These are likely due to cross-reactivity of different SzPs 
which share limited homology with SzPSe. Since SzP is highly variable among S. 
zooepidemicus strains (49-90%), the low background levels of antibodies observed in the 
placentitis group could be explained by colonization/infection with strains of S. 
zooepidemicus that express a different SzP. Donkey sera had high background reactivity 
with Se110.0 whereas reactivity in other groups was variable. 
Background levels of reactivity to S. zooepidemicus proteins were more frequent 
than to S. equi proteins. Given the ubiquitous presence of multiple S. zooepidemicus 
serovars in the tonsils of healthy horses  a possible explanation is that tonsillar carriage 
stimulates serum antibody background levels to MAP, FSR, Sz115, SzP, SKC proteins.  
 
5.4  Immune responses of mares with S. zooepidemicus placentitis 
 Sera from placentitis cases were included based on a recent analysis of 
MLSTs of S. zooepidemicus which revealed that S. zooepidemicus isolated from the same 
site of infection were genetically similar suggesting certain STs were adapted to the 
respiratory or reproductive tract (Webb et al., 2008). S. zooepidemicus in the reproductive 
tract might therefore elicit antibodies with specificities not elicited by isolates from the 
respiratory tract. Analysis of 253 S. zooepidemicus and 24 S. equi revealed that S. equi is 
more closely related to S. zooepidemicus from the reproductive tract than to S. 
zooepidemicus from respiratory tract infections (Webb 2008). Thus, differences in 
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antibody response relative to site of infection may advance understanding of organ 
specific differences in immune response to S. equi and S. zooepidemicus. 
 One of 5 convalescent sera from placentitis cases showed increased OD to a 
single S. zooepidemicus protein (MAP). Reactivities of pre infection sera to many of the 
proteins was high. Failure to detect increases in antibody to placentitis cases could be 
explained by the short duration of the experimental study. Sera were collected 10-27 days 
after infection (PI). Uterine infections are often localized and affected mares rarely 
present clinical signs, abnormal blood counts or changes in clinical chemistry (LeBlanc, 
2010). Specific antibodies against S. zooepidemicus could potentially be restricted to the 
uterus. 
 Unlike sera from cases of respiratory S. zooepidemicus infection, sera 
from placentitis cases had low levels of HylC specific antibody. Hyaluronidase cleaves 
HA in host tissues and may aid in spread of the bacteria.  
Ascending infection from the vagina to the uterus is blocked by a mucus plug in 
the cervical canal. The plug provides a barrier between the uterine environment and non-
sterile cranial vagina. SZ115 produced by S. zooepidemicus could potentially aid the 
bacteria in passing the mucus plug playing an important role in invasion of the organism 
into the uterus. Mares that were used as a source of sera had the mucus plug removed 
prior to inoculation of S. zooepidemicus. In vivo studies aimed to better understand the 
role of Sz115 in S. zooepidemicus uterine infection would require inoculation of the 
organism without removal of the mucus plug.  
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5.5 Immune response of donkeys  
 Horses and donkeys present different clinical signs in response to infection 
by several pathogens (eg. Equine herpesvirus-1 neurologic form, Pusterla et al., 2012; 
equine infectious anemia virus, Sala et al., 2012; Burkholderia mallei, Altemann et al., 
2012;  Amblyoma cajennense, Castagnolli et al., 2003 and Szabo et al., 2004). In 
donkeys, S. equi lymphadenitis is more caseous than in horses and respiratory S. 
zooepidemicus causes a more severe bronchopneumonia than in horses.  
Serum antibody responses of donkeys differed from that of horses and ponies. 
Horse/pony sera had increased reactivity with S. equi proteins IdeE2, Se46.8, Se42.0 and 
Se18.9. Donkey sera did not. Differences in clinical signs and immunological responses 
of horses and donkeys may be genetically mediated. 
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Chapter six - Supplemental Material: Vaccination of ponies with modified live 
EHV-1 strain RacH encoding SeM, Se18.9 and IdeE. 
6.1 Introduction 
S. equi enters the host via mucosal epithelium; therefore protection from infection 
is likely to be facilitated by a strong mucosal immune response that counteracts the 
pathogen before it invades tonsillar tissue. Given the potential importance of mucosal 
antibodies for protection against strangles, a vaccine that elicits these antibodies but 
avoids use of an attenuated strain is highly desirable.  
Intranasal vaccination designed to stimulate mucosal immunity to S. equi using a 
variety of mucosal adjuvants and carriers has failed to protect against experimental 
challenge. Experimental intranasal vaccines using different carriers include: sucrose 
isobutyrate, cholera toxin and avirulent Salmonella typhimurium expressing F3 fragment 
of SeM (Nally et al., 2000; Sheoran et al., 2001 and 2002).  
Virus vector vaccines are of interest due to their ability to infect cells and express 
vectored exogenous peptide sequence for de novo synthesis. Synthesized peptides are 
then presented via MHC class I and MHC class II to stimulate both cellular and humoral 
immune responses. RacH is a live modified equine herpesvirus type 1 virus (EHV-1) 
formerly used as a vaccine to protect horses against EHV-1 abortion. A number of recent 
studies have investigated its potential as a vector for exogenous viral antigens (Trapp et 
al., 2005; Paillot et al, 2008; Rosas et al., 2007; Van de Walle et al., 2010). 
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RacH is an attractive vector due to its efficient delivery of foreign genes to a 
variety of cell types, stable and efficient expression of immunogenic proteins even when 
in low concentrations, and a high capacity for packing foreign DNA (more than 100kb) 
(Trapp et al., 2005). It induces humoral and cell mediated immunity and has established 
safety in the horse, several other animal species and humans. 
Attenuation of RacH was achieved by cloning the virus as infectious bacterial 
artificial chromosomes (BAC) by inserting mini-F plasmid sequences into nonessential 
genomic regions (Rudolph et al., 2002; Rudolph and Osterrieder, 2002). Serial passages 
of these BACs on primary swine kidney cells cause several changes in the genome 
including deletion of both copies of virulent gene 67 (IR6) (Hubert et al., 1996; Neubauer 
et al., 1999; Osterrieder et al.,1996). 
Experimental studies with RacH as a vector for equine influenza virus (H3N8) 
and West Nile virus have demonstrated serological immune response against antigens in 
the vaccines and reduction of clinical signs after challenge (Van de Walle et al., 2010; 
Rosas et al., 2007). 
 
6.2 Material and methods 
6.2.1 Construction of recombinant EHV-1 strain RacH encoding SeM, Se18.9 
and IdeE  
The EHV-1 strain RacH recombinants encoding S. equi genes were constructed in 
Berlin and provided by Dr. Gillian Perkins at Cornell University, Ithaca, NY. Briefly, the 
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nucleotide sequence of SeM and Se18.9 separated by an internal ribosomal binding site 
(SeM-IRES-Se18.9) were synthesized de novo by a commercial supplier (GenScript). 
IdeE sequence was separately synthesized by the same company. The sequences were 
then codon-optimized to enable efficient expression in mammalian cells.  
Two shuttle plasmids were constructed by cloning separately the SeM-IRES-
Se18.9 and IdeE sequences into pEP_CMV plasmid, resulting in control of the genes by 
the human cytomegalovirus immediate early promoter and the bovine growth hormone as 
a transcriptional terminator sequence. The pEP_CMVplasmid also contains a unique I-
SceI site and an aphAI gene conferring kanamycin resistance. These elements allow 
cloning into the RacH genome. Transfer constructs were generated by PCR and two-step 
Red recombination was used to insert the SeM-IRES-Se18.9 and IdeE genes into the 
infectious bacterial artificial chromosome (BAC) clone of the EHV-1 RacH (pRacH). 
DNA’s of pRacH_SeM-IRES-Se18.9 and pRacH_IdeE were isolated and the structure of 
the BAC recombinants was verified by restriction enzyme and PCR analysis (Figure 
6.2.1A). Expression of S. equi proteins by the recombinant viruses was verified by 
western blotting using antibodies raised in rabbits (against SeM and Se18.9) and mice 
(IdeE) (Figure 6.2.1B). 
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FIGURE 3 -   FIGURE 6.2.1A: Recombinant RacH _SeM-IRES-Se18.9 and 
RacH_IdeE virus. 
 
Provided by Dr.Klaus Osterrieder 
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FIGURE 4 -   FIGURE 6.2.1B: Expression of the S. equi proteins by the 
recombinant virus was verified by western blotting using antibodies raised in 
rabbits against SeM (60kDa) and Se1.9 (19kDa)) and in mice against IdeE 
(40kDa).  
 
 
Provided by Dr.Klaus Osterrieder 
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6.2.2 Vaccine composition 
Concentrations of the intramuscular (I/M) and intranasal (I/N) viruses were 2.5 x 
106/ml of pRacH_SeM-IRES-Se18.9 and 2.5 x 106/ml of pRacH_IdeE 
(RacH/SeM/Se18.9/IdeE) in minimum essential medium (MEM). The concentration of 
the pRacH (RacH WT) virus was 2.5 x 106/ml in MEM.  
 
6.2.3 Immunization 
Ten ponies received 1 mL each of RacH/SeM/Se18.9/IdeE I/M. Two ponies 
received 1 ml each of RacH/SeM/Se18.9/IdeE IN and were kept separate from other 
ponies for 24 hours. Six ponies received 2 mL each of RacH WT I/M. Two non-
vaccinated ponies were included with I/M vaccinated horses at all times to serve as starter 
ponies in future comingling challenge. Animals were boosted 15 days later with 
equivalent doses of respective vaccines. 
 
6.2.4 EHV-1 virus neutralization test 
 Pre (day 0) and post (day 64) sera from 3 I/M, and 2 I/N vaccinated ponies, 3 
RacH WT and post-sera (day 64) from non-vaccinated ponies were submitted to the 
University of Kentucky’s Veterinary Diagnostic Laboratory (UK-VDL), Lexington, KY 
for EHV-1 virus neutralization test (EHV-1 VN).     
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6.2.5 Bactericidal assay 
 Pre- and post- sera from each pony and control serum were incubated with 104 
CFU of S. equi CF32 in early exponential phase of growth and fresh horse serum C as a 
complement source for 30 min at 37 °C with gentle rotation. Opsonized bacteria were 
then added to 1 mL of heparinized equine blood from a naïve donor. Half of the 
suspension was placed on ice (t0) and the other half was incubated for 90 min (t90) at 
37 °C with gentle rotation.  Triplicate aliquots of t0 and t90 were then plated onto pour 
plates consisting of 15 mL THB agar at 56 °C, 500 μL heparinized horse blood and 
150 μL test sample (bacteria and blood).  Colonies were counted after overnight 
incubation at 37 °C and percent reduction in counts from t0 to t90 calculated. 
 
6.2.6 Determination of antibody levels  
Antibody levels in sera collected on day 0 (Pre) and day 64 (Post) were examined 
by ELISA as described above. 
 
6.2.7 Control sera 
Positive and negative control sera for antibody to S. equi proteins are described 
above. Hyperimmune serum 724 was from a horse experimentally infected with S. 
equi CF32 and had a SeM ELISA titer of 1:6400. This serum was used as positive control 
for the bactericidal assay.  
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6.2.8 Statistical analysis 
A paired t-test was used to compare the means of ELISA OD490nm values of pre 
and post serum in each treatment group of RacH vaccination (I/M, I/N, RacH WT and 
non-vaccinated) for SeM-N2, IdeE and Se18.9. A one-way ANOVA was used to 
compare the fold increase between pre and post serum among treatment groups for each 
protein. Significance was set at p<0.05 for all statistical analyses. 
 
6.3 Results 
6.3.1 EHV-1 virus neutralization test 
 
Titers for EHV-1 VN test were performed on pre (day 0) and post (day 64) sera 
from a representative random selection of horses from each vaccination group. Titers ≥ 4 
fold higher in post than in  pre-serum were regarded as an affect of vaccination and/or of 
EHV-1 infection. Two of 3 ponies tested from each IM and RacH WT groups and 1 of 2 
IN vaccinated ponies showed increased serum neutralizing antibodies to EHV-1. Non-
vaccinated ponies showed low titers (1:16) in post serum. Titers varied from 1:4- 1:128 in 
the pre serum and 1:16- 1:256 in the post serum (Table 6.3.1).  
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TABLE 6 - TABLE 6.3.1: Titers of neutralizing antibody to Equine Herpesvirus type 1 
(EHV-1) of sera from randomly selected ponies vaccinated with EHV-1 modified live 
RacH as a vector for three recombinant antigens of S. equi SeM, IdeE and Se18.9. Pre 
(day 0) and post (day 64) sera from each treatment group were tested. 
Group Pony EHV-1 VN pré 
EHV-1 VN 
post   
Fold 
increase 
IM 
50 1:4 1:128 ≥ 4 
54 1:8 1:128 ≥ 4 
64 1:128 1:256 ≤ 4 
IN 
51 1:128 1:256 ≤ 4 
67 1:4 1:64 ≥ 4 
RacH WT 
53 1:64 1:16 ≤ 4 
57 1:64 1:256 ≥ 4 
60 1:8 1:256 ≥ 4 
No vac 
56 - 1:16 - 
66 - 1:16 - 
A four- fold or greater increase in titer is presumptive evidence of EHV-1 infection or 
vaccination. 
 
6.3.2 SeM-N2, IdeE or Se18.9 in RacH specific antibody ELISA’s. 
Paired t-tests were used to compare the means of ELISA OD490nm values of pre 
and post serum in each treatment group for SeM-N2, IdeE and Se18.9 (Table 6.3.2). 
Although changes in ODs of pre and post serum were higher for SeM-N2 and IdeE in the 
I/M and WT treatment groups, pre sera showed  high background --- increases in ODs in 
the post sera were ≤ 2 x the pre serum for IdeE. Furthermore, pre and post sera for SeM-
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N2 were 12 fold lower than the positive control.  One way ANOVA was used to compare 
the fold increase between pre and post sera among treatment groups for each protein. 
Differences among groups were significant for SeM-N2 and Se18.9. 
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TABLE 7 - TABLE 6.3.2: ELISA OD490 nm values for SeM-N2, IdeE or Se18.9 
specific antibody in sera.  Treatment groups were 1, intramuscular (I/M) and intranasal 
(I/N) vaccination with RacH/ SeM-N2/IdeE/Se18.92, intramuscular vaccination with 
RacH wild type (WT) and non –vaccinated (non vac). Serum was diluted 1:100. 
Treatment 
group pony 
SeM-N2 IdeE Se18.9 
pre post Pré post pre post 
IM 
50 0.18 0.23 2.2 2.2 0.91 0.90 
52 0.17 0.32 1.4 1.9 2.13 2.40 
54 0.19 0.42 1.9 2.9 0.68 0.70 
55 0.14 0.20 2.1 2.6 0.70 0.73 
59 0.13 0.16 2.1 2.2 0.88 0.71 
62 0.11 0.15 1.2 1.8 0.66 0.60 
64 0.11 0.18 1.2 1.4 0.86 1.16 
65 0.11 0.18 1.6 2.0 0.88 1.50 
68 0.16 0.84 2.0 2.4 0.67 1.00 
69 0.10 0.26 1.2 1.5 0.60 0.98 
IN 
51 0.11 0.11 1.7 1.4 0.42 0.44 
67 0.09 0.11 1.2 1.2 2.30 2.50 
RacH WT 
53 0.11 0.24 1.5 2.4 1.35 1.78 
57 0.11 0.18 1.6 1.9 0.73 1.94 
58 0.09 0.15 1.1 1.6 1.40 1.20 
60 0.19 0.2 1.3 1.9 0.65 0.62 
61 0.15 0.25 1.0 1.2 0.64 0.86 
63 0.18 0.23 1.5 1.7 1.66 1.40 
Non vac. 
56 0.13 0.13 1.4 1.4 1.00 1.09 
66 0.08 0.09 1.2 1.0 1.46 1.43 
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6.3.3 The effect of vaccination on serum bactericidal activity 
The serum from 2 ponies (one treated I/M and one non vaccinated) 
showedsignificant bactericidal activity on post serum. The vaccinated pony also showed 
bactericidal activity in the pre vaccination serum, suggesting bactericidal activity was not 
related to vaccination. Two ponies, one vaccinated IM and one IN showed very low 
levels of bactericidal activity post vaccination (Table 6.3.3).  
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TABLE 8 - TABLE 6.3.3: Bactericidal activities of sera from ponies before and after 
immunization with a live RacH vector of SeM, IdeE and Se18.9 peptides of S. equi. 
Treatment 
group pony 
% fold change 
pre post 
IM 
50 3 5 
52 - 0.5 1.4 
54 3 2.7 
55 1.5  1.2 
59 1.1 1.1 
62 2.7 2.2 
64 3.9 1.5 
65 3.8 2.5 
68 - 0.4 - 0.5 
69 2.6 - 0.1 
IN 
51 2.6 2.2 
67 2.8 0.1 
RacH WT 
53 5.8 3.4 
57 2.4   1.4 
58 - 0.1 - 0. 03 
60 - 0.6 2.7 
61 4.2 1.5 
63 1.8 1.9 
Non vac. 
56 2.7 1.5 
66 1.1 - 0.6 
*Blood was incubated with 104 CFU of early exponential phase S. equi CF32. Values are 
from 3 separate aliquots of blood from each pony. Bloods were rotated for 90 minutes at 
37 °C.  
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6.4 Conclusion  
In this study, we describe the antibody responses induced in horses by vaccination 
with a recombinant EHV-1 vaccine virus expressing S. equi proteins SeM, IdeE and 
Se18.9. 
Serum antibody responses to S. equi proteins SeM, IdeE and Se18.9 were not 
increased (OD490 nm ≥ 2 x) in the majority of the ponies post vaccination.  Eight of 8 
ponies tested showed varied levels of serum neutralizing antibodies to EHV-1 prior to 
vaccination (1:4 to 1:128) suggesting immune stimulation could have been impaired by 
anti-vector immunity. Results of EHV-1 virus neutralization tests performed on days 0 
and 64 demonstrated increase in antibody titer to EHV-1 in 5 of 8 ponies tested.  
Experimental study of RacH as a vector for equine influenza virus (H3N8) in 
horses with low EHV-1 VN antibody titers detected high levels of VN antibodies to 
RacH after primary vaccination. The vaccine was administered both I/M and 
subcutaneously (S/C). A booster dose was administered 25 days later, resulting in a 
robust serological immune response to equine influenza virus (Van de Walle et al., 2010). 
A second RacH vaccine expressing 2 West Nile virus (WNV) proteins administered I/M 
and S/C with boosters on days 31 and 45 induced specific IgG(T), IgGb to one of 2 WNV 
proteins (Rosas et al., 2007). In the present study, vaccination was administered I/M or 
I/N, and boosted once at day 15. The difference in administration route and booster 
interval and frequency could potentially account for the difference in success of inducing 
serum antibodies to vectored proteins. Additionally, RacH antigens could potentially be 
immunodominant over S. equi antigens or primary vaccination with 
 
 64 
RacH/SeM/IdeE/Se18.9 could potentially have stimulated VN antibodies to EHV-1 
capable of neutralizing RacH in the booster vaccine administered shortly after (day15). 
A more likely explanation is that differences in immune responses to virus versus 
bacterial proteins accounts for failure of stimulation of serum antibodies to S. equi 
proteins SeM, IdeE and Se18.9 vectored by  RacH.  
Horses have high rates of EHV-1 seroprevalence because EHV-1 is ubiquitous 
(Lunn et al., 2009). Foals as young as 30 days can become infected with EHV-1 and are 
likely to develop life-long latency (Foote et al., 2004; Allen et al., 2008, Paillot et al., 
2008).  Therefore vaccination with RacH as a vector requires  use of horses with low 
EHV-1 VN titers and involves an interval long enough to allow for decline of serum 
antibody to levels that will not block/neutralize the vector.  
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APPENDIX 
Table A: Reactivities (ELISA ODs) of pre and post infection sera of horses with 
proteins of S. equi. Values are means of triplicate readings. 
horses Se protein 
 SeM-N2 SzPSe Se110.0 Se75.3 
 Pre Post Pre Post Pre Post Pre Post 
Sz respiratory infection 
4 0.11 0.12 1.20 2.60 0.38 0.80 0.16 0.26 
49 0.12 0.12 1.20 1.10 0.73 0.57 0.18 0.20 
53 0.12 0.11 1.20 1.70 0.85 1.30 0.28 0.26 
54 0.12 0.11 1.20 1.40 0.48 0.84 0.26 0.19 
56 0.10 0.14 1.70 1.30 0.60 1.62 0.14 0.27 
59 0.11 0.10 1.50 1.30 0.84 1.45 0.20 0.25 
77 0.11 0.10 2.00 2.30 1.30 1.88 0.33 0.39 
912 0.10 0.12 2.00 2.30 1.30 1.88 0.33 0.39 
9801 0.10 0.13 1.40 1.30 0.25 0.66 0.20 0.17 
9802 0.10 0.12 0.94 1.40 0.37 0.90 0.19 0.20 
9803 0.11 0.14 1.15 1.20 0.45 0.58 0.19 0.26 
9804 0.12 0.14 1.40 1.60 0.26 0.46 0.18 0.27 
9805 0.11 0.11 1.15 1.32 0.39 0.73 0.30 0.25 
9807 0.12 0.12 1.20 1.10 0.78 1.10 0.19 0.23 
9808 0.09 0.09 0.50 1.20 0.36 1.10 0.15 0.25 
9809 0.01 0.11 0.60 1.50 0.45 1.56 0.14 0.19 
9810 0.10 0.14 0.72 0.80 0.33 0.90 0.14 0.20 
9812 0.10 0.10 0.45 1.13 0.27 0.78 0.10 0.10 
Sz placentitis 
D17 0.13 0.13 0.74 0.73 1.33 1.27 0.21 0.19 
L131 0.17 0.21 0.80 0.82 0.92 1.00 0.19 0.20 
K141 0.30 0.32 1.10 1.60 1.18 1.50 0.27 023 
643 0.12 0.11 0.96 1.40 0.87 0.90 0.33 0.27 
9907 0.15 0.15 0.62 0.65 1.16 1.24 0.23 0.37 
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Table A (continued) 
 
Strangles 
7 1.00 1.15 2.00 2.32 0.73 2.20  1.09 2.50 
8 0.90 1.75 1.30 2.30 0.90 1.16 1.80 2.40 
9 0.68 0.81 1.71 2.30 1.70 2.20 0.17 2.40 
10 0.90 1.10 1.80 2.20 0.80 1.90 0.16 2.30 
59 0.74 1.07 1.30 2.30 0.67 2.30 0.13 1.87 
Prince 0.92 1.50 1.50 2.20 0.50 1.90 0.17 1.10 
SF 0.69 0.86 1.10 2.20 1.10 2.40 0.37 2.40 
Donkeys 
Coco 0.10 0.20 1.70 1.70 1.50 1.54 0.80 0.64 
Jennie 0.11 0.12 1.60 1.70 1.34 1.45 1.00 1.0 
Lais 0.13 0.10 2.00 2.00 1.50 1.70 1.10 0.85 
Millie 0.12 0.10 2.30 3.30 1.10 0.90 0.86 0.70 
Rosie 0.17 0.15 1.90 1.80 1.30 1.30 0.90 0.77 
Shaggie 0.15 0.10 1.80 1.80 1.70 1.55 0.96 0.73 
Sheila 0.15 0.14 2.00 2.00 2.50 2.30 1.90 1.46 
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Table A (continued) 
 
horses Se protein 
 Se 46.8 Se 44.2 Se 42.0 Se 18.9 
 Pre Post Pre Post Pre Post Pre Post 
Sz respiratory infection 
4 0.19 0.20 0.42 0.65 0.11 0.13 1.65 1.57 
49 0.18 0.24 0.54 0.50 0.12 0.13 2.40 2.00 
53 0.24 0.25 0.50 0.52 0.14 0.12 2.26 2.15 
54 0.17 0.18 0.52 0.49 0.12 0.11 0.63 1.14 
56 0.18 0.25 0.55 0.52 0.10 0.13 2.20 1.08 
59 0.19 0.19 0.70 0.80 0.13 0.17 0.86 1.25 
77 0.19 0.20 0.54 0.48 0.12 0.12 0.65 1.08 
912 0.19 0.20 0.54 0.48 0.12 0.12 0.65 1.08 
9801 0.18 0.18 0.45 0.46 0.10 0.13 0.90 1.00 
9802 0.17 0.20 0.40 0.47 0.10 0.12 0.34 0.50 
9803 0.19 0.24 0.39 0.64 0.10 0.14 0.27 0.35 
9804 0.19 0.20 0.37 0.50 0.11 0.11 1.40 0.65 
9805 0.16 0.16 0.36 0.55 0.10 0.12 0.19 0.77 
9807 0.16 0.17 0.30 0.40 0.10 0.10 0.64 0.40 
9808 0.20 0.24 0.43 0.74 0.10 0.12 0.20 0.30 
9809 0.24 0.29 0.43 0.62 0.10 0.10 0.15 0.17 
9810 0.20 0.32 0.53 0.68 0.10 0.16 0.28 0.47 
9812 0.20 0.22 0.47 0.59 0.09 0.10 0.34 0.95 
Sz placentitis 
D17 0.24 0.21 0.62 0.60 0.09 0.10 0.30 0.23 
L131 0.26 0.27 0.56 0.63 0.10 0.10 0.35 0.50 
K141 0.27 0.30 0.77 0.88 0.14 0.13 0.63 0.64 
643 0.27 0.29 1.27 1.30 0.11 0.11 1.15 1.40 
9907 0.28 0.30 1.23 1.28 0.15 0.16 1.00 0.97 
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Table A (continued) 
 
Strangles 
7 1.20 2.40 0.54 2.42 0.35 0.94 1.40 2.30 
8 1.20 2.20 0.26 2.31 0.40 0.80 0.34 2.30 
9 0.46 2.00 0.26 2.20 0.28 0.90 0.54 2.20 
10 0.62 1.90 0.27 2.10 0.26 0.89 0.43 2.36 
59 0.88 1.96 0.18 1.60 0.15 0.24 0.25 2.30 
Prince 0.80 2.30 0.24 1.94 0.31 0.96 0.44 2.13 
SF 1.10 2.20 0.17 2.20 0.60 0.11 0.20 2.40 
Donkeys 
Coco 0.13 0.16 0.40 0.35 0.10 0.20 0.90 0.70 
Jennie 0.15 0.14 0.56 0.50 0.10 0.10 1.62 1.30 
Lais 0.16 0.20 0.63 0.72 0.23 0.36 0.45 0.50 
Millie 0.17 0.20 0.37 0.50 0.20 0.20 0.66 0.60 
Rosie 0.22 0.20 0.55 0.46 0.13 0.11 1.10 0.90 
Shaggie 0.14 0.14 0.23 0.20 0.13 0.11 0.30 0.23 
Sheila 0.25 0.24 1.10 0.67 0.31 0.20 0.72 0.50 
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Table B: Reactivities (ELISA ODs) of pre and post infection sera of horses with 
proteins of S. zooepidemicus. Values are means of triplicate readings. 
Horse 
Protein 
ENO SzM OppA MAP FSR 
 Pre Post Pre Post Pre Post Pre Post Pre Post 
Sz respiratory infection 
4 0.12 0.14 0.53 1.60 0.35 0.40 0.60 1.93 0.82 1.62 
49 0.13 0.14 0.70 0.60 0.40 0.36 0.80 0.86 0.93 0.80 
53 0.11 0.10 0.63 0.51 0.70 1.00 1.25 1.33 0.90 1.20 
54 0.12 0.10 0.52 0.42 0.32 0.40 0.70 0.65 0.78 1.15 
56 0.10 0.14 0.53 0.65 0.24 0.30 0.97 1.40 0.84 1.36 
59 0.11 0.11 0.50 0.50 0.35 0.35 0.86 0.83 1.60 1.52 
77 0.10 0.13 0.64 0.51 0.30 0.46 0.76 1.00 0.63 1.00 
912 0.15 0.17 0.78 0.80 0.46 0.35 1.86 2.30 1.20 1.11 
9801 0.13 0.17 1.00 0.70 0.28 0.50 1.12 1.35 0.93 1.00 
9802 0.12 0.16 0.65 0.77 0.18 0.34 0.73 1.27 0.67 1.14 
9803 0.14 0.20 0.80 0.80 0.40 0.44 0.71 0.71 1.00 1.00 
9804 0.14 0.16 1.00 0.88 0.28 0.37 1.10 0.88 0.51 0.78 
9805 0.12 0.14 0.76 0.80 0.19 0.26 0.77 1.34 0.37 1.24 
9807 0.11 0.13 0.75 0.80 0.26 0.28 1.23 1.90 1.23 1.30 
9808 0.14 0.16 0.60 0.95 0.21 0.65 0.80 2.20 0.77 1.70 
9809 0.13 0.15 0.72 0.80 0.50 0.60 0.60 1.60 0.85 1.20 
9810 0.14 0.35 0.72 0.80 0.50 0.60 0.60 1.60 0.85 1.20 
9812 0.14 0.15 0.75 1.40 0.30 0.80 1.15 1.80 0.70 1.10 
Sz placentitis 
D17 0.26 0.27 1.57 1.57 0.47 0.50 1.50 1.62 1.20 1.23 
L131 0.24 0.22 2.00 1.98 1.26 1.40 0.60 1.20 1.73 1.81 
K141 0.35 0.36 1.71 1.60 0.50 0.70 1.90 1.80 1.23 1.50 
643 0.25 0.26 1.28 1.28 0.63 0.75 1.91 1.60 1.40 1.37 
9907 0.35 0.36 1.67 2.10 0.60 0.66 1.24 2.00 1.45 1.50 
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Table B (continued) 
 
Strangles 
2 0.96 0.10 0.78 1.08 0.47 0.55 2.19 2.32 1.52 1.50 
6 0.10 0.10 0.73 1.13 0.29 0.14 1.43 2.24 1.77 1.30 
7 0.08 0.09 0.70 0.97 0.56 0.79 1.10 1.61 1.70 1.50 
8 0.09 0.10 0.95 1.63 0.27 0.93 1.10 1.79 1.64 1.50 
9 0.12 0.10 0.86 1.13 0.51 1.59 1.07 0.85 2.50 1.51 
10 0.09 0.13 0.73 0.93 0.20 0.48 0.56 1.04 1.10 1.37 
59 0.07 0.12 0.58 0.92 0.19 0.39 1.00 1.80 1.20 1.52 
Prince 0.08 0.09 0.80 1.57 0.33 0.49 1.80 1.93 1.22 0.62 
SF 0.09 0.10 0.72 1.00 0.21 1.14 0.64 1.89 0.80 1.07 
Donkey 
Coco 0.13 0.15 1.00 0.82 0.25 0.28 2.16 1.97 1.77 1.76 
Jennie 0.10 0.11 0.80 0.70 0.52 0.40 2.30 2.16 1.76 1.79 
Lais 0.19 0.17 1.50 1.30 0.42 0.66 2.30 2.20 2.80 1.80 
Millie 0.13 0.18 1.30 1.23 0.42 0.49 2.30 2.40 1.60 1.62 
Rosie 0.20 0.17 1.46 1.59 0.55 0.47 2.12 2.10 1.60 1.64 
Shaggie 0.13 0.11 1.08 0.79 0.36 0.28 2.20 2.10 2.04 1.90 
Sheila 0.13 0.13 0.90 1.32 0.69 0.69 2.20 2.00 1.88 2.00 
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Table C: Reactivities (ELISA ODs) of pre and post infection sera of horses with 
proteins of S. zooepidemicus. Values are means of triplicate readings. 
Horse 
Sz protein 
INLA Sz115 MAC ScpC SzP 
 Pre Post Pre Post Pre Post Pre Post Pre Post 
Sz respiratory infection 
4 0.30 0.40 1.40 2.00 0.44 0.80 0.53 1.20 0.35 0.90 
49 0.30 0.40 1.60 1.00 0.36 0.36 1.00 0.64 0.40 0.53 
53 0.30 0.43 2.00 2.10 0.35 0.43 0.87 1.08 0.40 0.70 
54 0.22 0.30 1.10 1.77 0.40 0.40 0.46 0.88 0.33 0.50 
56 0.27 0.40 1.90 1.80 0.40 0.50 0.64 0.98 0.46 0.65 
59 0.30 0.50 2.20 2.10 1.50 0.90 1.00 1.20 0.54 0.52 
77 0.24 0.30 1.10 2.00 0.41 0.30 0.75 0.40 0.50 0.60 
912 0.45 0.60 2.40 2.30 0.90 0.85 2.20 2.50 1.70 1.90 
9801 0.40 0.30 2.50 2.60 0.30 0.40 0.72 1.40 1.20 1.54 
9802 0.23 0.34 0.95 2.40 0.50 0.50 0.95 1.80 0.86 1.50 
9803 0.37 0.53 1.80 2.10 0.60 0.60 0.90 1.20 1.44 1.80 
9804 0.30 0.50 1.70 2.40 0.30 0.37 0.82 1.20 1.00 1.66 
9805 0.28 0.30 0.80 1.77 0.40 0.54 0.53 1.30 0.67 1.33 
9807 0.40 0.50 1.37 2.40 0.30 0.50 1.60 2.20 1.20 1.10 
9808 0.30 0.38 1.45 2.80 0.65 1.16 1.00 1.80 1.47 2.40 
9809 0.36 0.50 1.00 2.70 0.55 0.56 1.20 2.34 1.34 2.20 
9810 0.40 1.00 1.33 2.20 0.80 0.65 0.88 1.87 1.27 1.60 
9812 0.23 0.40 0.86 2.60 0.33 0.40 0.68 1.60 0.71 2.00 
Sz placentitis 
D17 0.50 0.47 1.44 1.40 0.68 0.64 2.14 2.08 1.70 1.63 
L131 0.77 0.79 1.46 1.65 0.68 0.73 1.66 1.69 2.00 2.10 
K141 0.64 0.70 1.38 2.30 0.87 0.96 2.20 2.70 2.15 2.80 
643 0.43 0.47 1.86 2.20 0.82 0.94 1.50 1.41 1.97 2.77 
9907 0.65 0.71 2.00 2.15 0.97 0.95 1.86 1.86 1.46 1.57 
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Table C (continued) 
 
Strangles 
2 0.62 0.53 2.00 2.55 1.26 1.90 1.97 1.98 1.25 1.70 
6 0.31 0.33 2.47 2.88 1.10 2.50 1.70 2.00 1.60 2.30 
7 0.33 0.33 1.33 2.29 1.19 2.35 1.00 1.09 1.60 2.37 
8 0.47 0.45 2.00 2.72 1.93 2.12 1.57 1.63 1.10 2.26 
9 0.48 0.40 2.70 2.37 2.40 2.10 2.44 2.11 1.67 2.20 
10 0.40 0.68 1.90 2.50 1.19 1.90 1.15 1.30 1.59 2.30 
59 0.48 0.48 1.45 2.87 1.00 2.18 1.28 1.43 1.18 2.07 
Prince 0.41 0.52 3.00 3.00 0.90 1.76 2.20 1.90 1.33 1.80 
SF 0.36 0.68 1.59 2.85 0.77 1.71 1.57 2.52 1.25 2.34 
Donkey 
Coco 0.80 0.84 2.20 2.40 0.34 0.35 1.44 1.50 1.67 1.54 
Jennie 0.82 0.83 2.44 2.40 0.28 0.33 2.17 2.15 1.60 1.55 
Laís 0.66 0.72 2.20 2.20 1.09 0.77 1.20 1.10 1.80 1.77 
Millie 0.56 0.72 2.20 2.20 1.09 0.77 1.20 1.10 1.80 1.77 
Rosie 0.39 0.38 1.78 1.47 0.76 0.67 1.40 1.50 1.80 1.60 
Shagg 0.46 0.40 1.85 1.46 0.32 0.28 1.90 1.80 1.70 1.66 
Sheila 0.56 0.77 2.30 2.30 1.10 0.70 1.70 1.50 1.80 1.80 
 
 
 
 
 89 
Table C (continued) 
 
Horse 
 
SKC AhpC GAPDH HylC 
 Pre Post Pré Post Pre Post Pre Post 
 Sz respiratory infection 
4 1.25 2.30 0.19 0.23 0.20 0.24 0.28 1.23 
49 0.80 0.80 0.21 0.26 0.23 0.25 0.36 0.50 
53 1.12 1.47 0.20 0.21 0.23 0.23 0.34 0.80 
54 0.90 0.99 0.22 0.20 0.21 0.18 0.30 0.30 
56 0.80 1.30 0.18 0.28 0.20 0.30 0.30 0.55 
59 1.13 1.70 0.18 0.18 0.20 0.20 0.32 1.00 
77 0.80 1.30 0.17 0.20 0.19 0.27 0.26 0.80 
912 1.77 2.10 0.20 0.22 0.22 0.24 0.32 0.56 
9801 1.70 2.40 0.24 0.23 0.23 0.26 0.28 0.42 
9802 1.10 2.20 0.14 0.23 0.17 0.24 0.24 0.50 
9803 1.90 2.30 0.15 0.27 0.18 0.30 0.33 0.75 
9804 0.90 1.70 0.19 0.24 0.20 0.25 0.24 0.83 
9805 0.48 1.30 0.15 0.20 0.19 0.25 0.20 0.20 
9807 1.60 2.20 0.15 0.20 0.19 0.23 0.27 0.30 
9808 1.40 3.00 0.14 0.19 0.20 0.24 0.30 0.86 
9809 1.40 2.90 0.17 0.24 0.20 0.24 0.29 0.26 
9810 1.30 1.96 0.13 0.26 0.19 0.40 0.33 1.20 
9812 1.40 2.70 0.16 0.17 0.21 0.22 0.30 0.42 
 Sz placentitis 
D17 1.88 1.80 0.25 0.29 0.34 0.35 0.35 0.39 
L131 2.70 2.70 0.15 0.23 0.21 0.30 0.35 0.43 
K141 1.99 2.50 0.44 0.20 0.56 0.33 0.60 0.85 
643 2.55 3.00 0.35 0.19 0.46 0.26 0.60 0.53 
9907 2.30 2.50 0.4 0.40 0.53 0.54 0.50 0.42 
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Table C (continued) 
 
 Strangles 
2 1.57 1.95 0.15 0.18 0.18 0.21 - - 
6 1.98 2.50 0.26 0.26 0.24 0.28 - - 
7 1.71 2.12 0.20 0.78 0.19 0.58 - - 
8 2.14 2.36 0.20 0.25 0.20 0.29 - - 
9 2.40 1.96 0.22 0.25 0.25 0.27 - - 
10 1.40 1.88 0.20 0.50 0.24 0.54 - - 
59 1.14 2.16 0.16 0.18 0.15 0.19 - - 
Prince 2.20 2.26 0.18 0.22 0.17 0.20 - - 
SF 1.25 2.88 0.17 0.22 0.16 0.16 - - 
 Donkey 
Coco 2.00 2.00 0.18 0.27 0.20 0.27 - - 
Jennie 2.20 2.20 0.14 0.14 0.18 0.17 - - 
Laís 1.99 1.90 0.19 0.18 0.34 0.30 - - 
Millie 1.99 1.90 0.19 0.18 0.34 0.30 - - 
Rosie 1.58 1.75 0.22 0.18 0.28 0.24 - - 
Shagg 2.97 1.80 0.50 0.28 0.37 0.25 - - 
Sheila 1.90 2.96 0.30 0.25 0.25 0.27 - - 
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